{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:34:43Z","timestamp":1790386483115,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.det.2021.05.010","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T03:40:40Z","timestamp":1622518840000},"page":"545-553","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["The Use of Biologics During the COVID-19 Pandemic"],"prefix":"10.1016","volume":"39","author":[{"given":"Madison E.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison H.","family":"Kucharik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P.","family":"Pourali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca M.","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.det.2021.05.010_bib1","first-page":"e13475","article-title":"Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during RED-ZONE declaration","author":"Damiani","year":"2020","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.det.2021.05.010_bib2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41577-020-0312-7","article-title":"COVID-19: risk for cytokine targeting in chronic inflammatory diseases?","volume":"20","author":"Schett","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"19","key":"10.1016\/j.det.2021.05.010_bib3","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: A review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.det.2021.05.010_bib4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2020.08.095","article-title":"Effect of anti\u2013tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in patients with psoriasis\u2014A meta-estimate of pivotal phase 3 trials relevant to decision making during the COVID-19 pandemic","volume":"84","author":"Syed","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2021.05.010_bib5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMc2009567","article-title":"Covid-19 in immune-mediated inflammatory diseases\u2014case series from New York","volume":"383","author":"Haberman","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.det.2021.05.010_bib6","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.jaad.2020.07.089","article-title":"Antecedent immunosuppressive therapy for immune-mediated inflammatory diseases in the setting of a COVID-19 outbreak","volume":"83","author":"Veenstra","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2021.05.010_bib8","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaad.2020.08.026","article-title":"The risk of respiratory tract infections and interstitial lung disease with IL-12\/23 and IL-23 antagonists in patients with autoimmune diseases: a systematic review and meta-analysis","volume":"84","author":"Akiyama","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2021.05.010_bib9","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jaad.2020.05.035","article-title":"The risk of respiratory tract infections and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: A meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic","volume":"83","author":"Wan","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2021.05.010_bib10","doi-asserted-by":"crossref","DOI":"10.4081\/dr.2020.8642","article-title":"Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces","volume":"12","author":"Vispi","year":"2020","journal-title":"Dermatol Rep"},{"issue":"1","key":"10.1016\/j.det.2021.05.010_bib11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jaad.2020.04.085","article-title":"Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment","volume":"83","author":"Gisondi","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2021.05.010_bib12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaci.2020.10.007","article-title":"Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study","volume":"147","author":"Mahil","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.det.2021.05.010_bib13","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jaad.2020.09.001","article-title":"National psoriasis foundation COVID-19 task force guidance for management of psoriatic disease during the pandemic: Version 1","volume":"83","author":"Gelfand","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2021.05.010_bib15","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/j.jaad.2020.04.030","article-title":"Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations","volume":"83","author":"Blaszczak","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2021.05.010_bib16","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.det.2021.05.010_bib17","first-page":"e13680","article-title":"Moderate to severe hidradenitis suppurativa under systemic therapy during the COVID-19 outbreak","volume":"33","author":"Giulia","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.det.2021.05.010_bib18","first-page":"1","article-title":"Biologics for patients affected by Hidradenitis suppurativa in the COVID-19 era: data from a referral centre of Southern Italy","author":"Marasca","year":"2020","journal-title":"J\u00a0Dermatol Treat"},{"issue":"3","key":"10.1016\/j.det.2021.05.010_bib22","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/j.jaad.2020.06.015","article-title":"Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic","volume":"83","author":"Kearns","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.det.2021.05.010_bib23","doi-asserted-by":"crossref","first-page":"e303","DOI":"10.1111\/jdv.16527","article-title":"Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports","volume":"34","author":"Ferrucci","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"8","key":"10.1016\/j.det.2021.05.010_bib24","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1111\/jdv.16619","article-title":"SARS-CoV-2 asymptomatic infection in a patient under treatment with dupilumab","volume":"34","author":"Caroppo","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.det.2021.05.010_bib25","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jaci.2020.05.005","article-title":"COVID-19 in a patient with severe chronic rhinosinusitis with nasal polyps during therapy with dupilumab","volume":"146","author":"F\u00f6rster-Ruhrmann","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.det.2021.05.010_bib26","doi-asserted-by":"crossref","first-page":"e13502","DOI":"10.1111\/dth.13502","article-title":"Dupilumab and COVID-19: what should we expect?","volume":"33","author":"Patruno","year":"2020","journal-title":"Dermatol Ther"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863521000474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863521000474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T02:05:56Z","timestamp":1718762756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863521000474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0733863521000474"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2021.05.010","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Use of Biologics During the COVID-19 Pandemic","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2021.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}